close-icon

Log In to Bolder Science

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.

close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

  • Clinicaltrials.gov identifier

    NCT03601078

  • Recruitment Status

    Recruiting

  • First Posted

    July 26, 2018

  • Last update posted

    June 24, 2022

Study Description

Brief summary:

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1), in subjects with MM having progressed within one 18 months of initial treatment including autologous stem cell transplantation (ASCT) (Cohort 2a), and without ASCT (Cohort 2b) or, in subjects with inadequate response post ASCT during initial treatment (Cohort 2c). Approximately 235 subjects will be enrolled into one of three cohorts. Cohort 1 will enroll approximately 97 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2a will enroll approximately 39 MM subjects, with 1 prior anti-myeloma therapy including ASCT and with early relapse. Cohort 2b will enroll approximately 39 MM subjects with 1 prior anti-myeloma therapy not including ASCT and with early relapse. Cohort 2c will enroll approximately 30 MM subjects with inadequate response to ASCT during their initial anti-myeloma therapy. The cohorts will start in parallel and independently. Cohort 3 will enroll approximately 30 newly diagnosed multiple myeloma (NDMM) participants with suboptimal response to ASCT.

  • Condition or Disease:Multiple Myeloma
  • Intervention/Treatment: Biological: bb2121
    Drug: Lenalomide
  • Phase: Phase 2

Detailed Description

Anti-myeloma bridging treatment is allowed for disease control while bb2121 is being manufactured for cohorts 1, 2a and 2b only.

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 235 participants
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
  • Actual Study Start Date: December 2018
  • Estimated Primary Completion Date: December 2023
  • Estimated Study Completion Date: December 2030

Arms and interventions

Arm Intervention/treatment
Experimental: BB2121 with lenalidomide in newly diagnosed multiple myeloma
Biological: bb2121
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

Drug: Lenalomide
Specified dose on specified days
Experimental: bb2121 in relapsed and refractory multiple myeloma patients
bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
Biological: bb2121
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

Outcome Measures

  • Primary Outcome Measures: 1. Overall response rate (ORR)- Cohort 1 [ Time Frame: Up to approximately 5 years ]
    Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
  • 2. Complete response (CR) rate - Cohort 2a , b, c and Cohort 3 [ Time Frame: Up to approximately 5 years ]
    Percentage of subjects who achieved CR or stringent CR according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
  • Secondary Outcome Measures: 1. Complete response (CR) rate - Cohort 1 [ Time Frame: Up to approximately 5 years ]
    Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
  • 2. Overall response rate (ORR) - Cohort 2a, b, c and Cohort 3 [ Time Frame: Up to approximately 5 years ]
    Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
  • 3. Very good partial response (VGPR) rate - Cohort 2c [ Time Frame: Minimum of 2 years after bb2121 infusion ]
    Percentage of subjects who achieved VGPR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigator
  • 4. Time to response (TTR) [ Time Frame: Minimum of 2 years after bb2121 infusion ]
    Time from first bb2121 infusion to first documentation of response (PR or greater)
  • 5. Duration of response (DoR) [ Time Frame: Minimum of 2 years after bb2121 infusion ]
    Time from first documentation of response (PR or greater) to first documentation of progressive disease (PD) or death from any cause, whichever occurs first
  • 6. Progression-free survival (PFS) [ Time Frame: Minimum of 2 years after bb2121 infusion ]
    Time from first bb2121 infusion to first documentation of PD, or death due to any cause, whichever occurs first
  • 7. Time to progression (TTP) [ Time Frame: Minimum of 2 years after bb2121 infusion ]
    Time from first bb2121 infusion to first documentation of PD
  • 8. Overall survival (OS) [ Time Frame: Minimum of 2 years after bb2121 infusion ]
    Time from first bb2121 infusion to time of death due to any cause
  • 9. Adverse Events (AEs) [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Type, frequency, seriousness and severity of adverse events (AEs), adverse events of special interest (AESIs) (including cytokine release syndrome, neurotoxicity and infection), and relationship of AE to study drug.
  • 10. Percentage of participants who received lenalidomide maintenance for the first 3 cycles following bb2121 infusion with at least 75% dose compliance - Cohort 3 [ Time Frame: Up to 3 months ]
  • 11. Pharmacokinetics - Cmax [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Maximum expansion of bb2121 chimeric antigen receptor (CAR) T cells
  • 12. Pharmacokinetics - tmax [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Time to peak of bb2121 CAR T cells
  • 13. Pharmacokinetics - AUC [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Area under the curve of CAR T cells
  • 14. Pharmacokinetics - tlast [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Time to last measurable CAR T cells
  • 15. Pharmacokinetics - AUC0-28days [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Area under the curve of CAR T cells from time zero to Day 28
  • 16. Immunogenicity [ Time Frame: Minimum of 2 years after bb2121 infusion ]
    Development of an anti-CAR antibody response
  • 17. Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30) [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Questionnaire will be used as a measure of health-related quality of life
  • 18. Subject-reported outcomes as measured by EuroQoL Group EQ-5D-5L Health Questionnaire [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal
  • 19. Subject-reported outcomes as measured by EORTC-QLQ-MY20 [ Time Frame: Minimum 5 years after bb2121 infusion ]
    Is a 20-item myeloma module intended for use among patients varying in disease stage and treatment modality

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF) For Cohorts 1 and 2 only, participant has measurable disease, defined as: M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP ≥ 0.5 g/dL or uPEP ≥ 200 mg/24 hours and/or Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio Subjects with one of the following cohort specific requirements: Cohort 1 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens: Subject must have received at least 3 prior anti-myeloma treatment regimens. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen Subject must have undergone at least 2 consecutive cycles of treatment for each regimen, unless PD was the best response to the regimen Subject must have received prior treatment with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody Subject has evidence of PD on or within 60 days of the most recent prior treatment regimen Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen Cohort 2 subjects with 1 prior anti-myeloma treatment regimen: Subject must have received only 1 prior anti-myeloma treatment regimen. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen Subject must have the following HR factors: Early relapse defined as: Cohort 2a: PD < 18 months since date of start of initial therapy. Initial therapy must contain induction, ASCT (single or tandem) and lenalidomide containing maintenance. Cohort 2b: PD < 18 months since date of start or initial therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone Cohort 2c: Subject must have received minimum 3 cycles of induction therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone. Subjects must have had ASCT (single or tandem AND < VGPR (excluding PD) at first assessment between 70 to 110 days after last ASCT, with initial therapy without consolidation and maintenance. Cohort 3 participants with newly diagnosed MM (NDMM) who received only induction and ASCT, without subsequent consolidation or maintenance Subject with NDMM who have received only induction and ASCT, without subsequent consolidation or maintenance Cohort 3 With NDMM who have received only induction and ASCT, without subsequent consolidation or maintenance Must have received 4 to 6 cycles of induction therapy which must contain at minimum, a proteasome inhibitor and an immunomodulatory agent and must have had single ASCT within 6 months prior to consent Must have achieved documented PR or VGPR at first post-ASCT assessment approximately 100 days after ASCT and this response must be maintained at screening Per Investigator's assessment, subject must be a candidate for single-agent lenalidomide maintenance Subject must have Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Subject must have recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: Subject used any investigational agents within 14 days prior to leukapheresis or, for Cohort 3, within 14 days prior to consent Subject received any of the following within the last 14 days prior to leukapheresis or, for Cohort 3, within 14 days prior to consent: Plasmapheresis Major surgery (as defined by the investigator) Radiation therapy other than local therapy for myeloma associated bone lesions Use of any systemic anti-myeloma drug therapy Subject with known central nervous system involvement with myeloma Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation History or presence of clinically relevant central nervous system (CNS) pathology Subject with active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or clinically significant amyloidosis Inadequate organ function Subject with a history of Class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to starting study treatment Ongoing treatment with chronic immunosuppressants Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy Subject has received ASCT within 12 weeks prior to leukapheresis Subject has history of primary immunodeficiency Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B or active hepatitis A or C Subject has uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment Subject with prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years Pregnant or lactating women Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab

Contacts and Locations

Contacts

Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com

Contact: First line of the email MUST contain the NCT# and Site #.

Locations

United States, Arizona
Mayo Clinic Arizona
Scottsdale

United States, Arizona
Mayo Clinic in Arizona - Scottsdale
Scottsdale

United States, California
UCSF Medical Center
San Francisco

United States, California
University Of California San Francisco Medical Center
San Francisco

United States, Florida
Moffitt Cancer Center
Tampa

United States, Florida
Moffitt Cancer Center
Tampa

United States, Georgia
Emory University
Atlanta

United States, Georgia
Emory University
Atlanta

United States, Massachusetts
Massachusetts General Hospital
Boston

United States, Massachusetts
Dana Farber Cancer Institute
Boston

United States, Massachusetts
Dana Farber Cancer Institute
Boston

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston

United States, Missouri
Washington University
Saint Louis

United States, Missouri
Washington University
Saint Louis

United States, Nebraska
University of Nebraska
Omaha

United States, Nebraska
University Of Nebraska
Omaha

United States, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack

United States, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack

United States, New York
Mt Sinai Medical Center - NY
New York

United States, New York
Mt Sinai Medical Center - NY
New York

United States, New York
Columbia University Medical Center / New York Presbyterian Hospital
New York

United States, New York
Columbia University Medical Center/New York-Presbyterian Hospital
New York

United States, New York
Memorial Sloan Kettering Cancer Center
New York

United States, North Carolina
Levine Cancer Institute
Charlotte

United States, North Carolina
Levine Cancer Institute
Charlotte

United States, Tennessee
Sarah Cannon Research Inst
Nashville

United States, Tennessee
Sarah Cannon Research Inst
Nashville

United States, Texas
University of Texas Southwestern Medical Center
Dallas

United States, Texas
University Of Texas Southwestern Medical Center
Dallas

United States, Texas
MD Anderson Cancer Center The University of Texas
Houston

United States, Texas
MD Anderson Cancer Center The University of Texas
Houston

United States, Washington
Swedish Cancer Inst
Seattle

United States, Washington
Swedish Cancer Inst
Seattle

United States, Wisconsin
Froedtert Hospital BMT Medical College of Wisconsin
Milwaukee

United States, Wisconsin
Froedtert Hospital BMT Medical College of Wisconsin
Milwaukee

France
CHU de Poitiers
Poitiers

France
Local Institution - 404
Poitiers

Germany
Local Institution - 506
Hamburg

Germany
Universitaetsklinkum Hamburg-Eppendorf
Hamburg

Germany
Local Institution - 505
Würzburg

Germany
Universitatsklinikum Würzburg
Würzburg

Italy
Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi
Bologna

Italy
Local Institution - 603
Bologna

Spain
Clinica Universitaria de Navarra
Pamplona

Spain
Local Institution - 703
Pamplona

Spain
Hospital Universitario de Salamanca
Salamanca

Spain
Local Institution - 704
Salamanca

United Kingdom
King's College HospitalGKT School of Medicine
London

United Kingdom
Local Institution - 801
London

Sponsors and Collaborators

Celgene

Investigators

Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

More Information

  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT03601078 History of Changes
  • Other Study ID Numbers: BB2121-MM-002, U1111-1216-4209, 2018-000264-28
  • First Posted: July 26, 2018 Key Record Dates
  • Last Update Posted: June 24, 2022
  • Last Verified: June 2022
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: Multiple Myeloma
    bb2121
    Relapsed and Refractory Multiple Myeloma
    High Risk Multiple Myeloma
    Phase 2
    Multi-cohort
    Open-label
  • Additional relevant MeSH terms: Multiple Myeloma
    Neoplasms, Plasma Cell
    Neoplasms by Histologic Type
    Neoplasms
    Hemostatic Disorders
    Vascular Diseases
    Cardiovascular Diseases
    Paraproteinemias
    Blood Protein Disorders
    Hematologic Diseases
    Hemorrhagic Disorders
    Lymphoproliferative Disorders
    Immunoproliferative Disorders
    Immune System Diseases